Clinical Trial Update: A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate [Phase 2]

View source ↗

Summary

Phase 2 study of dasatinib in chronic myeloid leukemia patients resistant or intolerant to imatinib has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2 | Phase 2 | Status: COMPLETED